ABSTRACT

Introduction

In light of the current Covid-19 pandemic and the ongoing, extensive debate about the use of biological agents in psoriatic patients, we felt compelled to relate our experience in the use of secukinumab in the same cohort before and during the lockdown in Italy. Areas covered: Secukinumab was not discontinued, and there were no cases of confirmed infection with SARS-CoV-2 in this cohort. Expert opinion: In our practice, there is no evidence favoring the discontinuation of secukinumab in these patients. We also present a brief commentary on the use of biological agents in patients with moderate-to-severe plaque psoriasis.

中文翻译：

---

经苏金单抗治疗的中重度斑块状牛皮癣患者的真实队列研究现状，以及在Covid-19时代使用生物制剂的考虑。

摘要

介绍

鉴于当前的Covid-19大流行以及关于银屑病患者使用生物制剂的广泛辩论，我们感到有必要在意大利禁闭之前和期间将我们在同一人群中使用secukinumab的经验联系起来。覆盖区域：未停止使用Secukinumab，该队列中无确诊为SARS-CoV-2感染的病例。专家意见：在我们的实践中，没有证据支持在这些患者中停用secukinumab。我们还对中度至重度斑块状牛皮癣患者使用生物制剂进行了简短评论。